This will bring the total number of deliveries by BioNTech-Pfizer to 650 million doses in 2022. These doses come on top of the 450 million doses already planned to be delivered in 2022 based on the agreement already signed. The Commission and Member States have also activated a first option to order over 200 million doses under the third contract with BioNTech-Pfizer. On 19 December 2021, the Commission agreed with BioNTech-Pfizer to accelerate deliveries of 20 million vaccine doses in Member States during the first quarter of 2022 (5 million in January, 5 million in February and 10 million in March), bringing the total number of deliveries for this period to 215 million. It will allow for the purchase of 900 million doses of the current vaccine and of a vaccine adapted to variants (if necessary and if approved), with the option to purchase an additional 900 million doses. It reserves an additional 1.8 billion doses on behalf of all EU Member States, between the end of 20. On, the European Commission signed a third contract with BioNTech-Pfizer.
#Redacted definition wiki free#
On 10 March 2021, the European Commission reached an agreement with BioNTech-Pfizer for the supply of 4 million additional doses of COVID-19 vaccines to tackle coronavirus hotspots and to facilitate free movement across borders.
On 8 January 2021, the Commission proposedto Member States to purchase an additional 200 million BioNTech-Pfizer vaccine doses, with the option to acquire another 100 million doses. On 15 December 2020, the Commission decided to purchase these 100 million additional doses.
#Redacted definition wiki plus#
The Advance Purchase Agreement with BioNTech-Pfizer provided for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to purchase up to a further 100 million doses. This followed a positive scientific recommendation by the European Medicines Agency. On 21 December 2020, the Commission granted a conditional marketing authorisation for the COVID‑19 vaccine developed by BioNTech and Pfizer, making it the first COVID-19 vaccine authorised in the EU. Safe and effective vaccines started to be distributed in the EU by the end of 2020, following strict authorisation procedures and the highest safety standards. The vaccine strategy should act as a reference point for Member States when formulating their national vaccination strategies. to make sure that preparations are made in EU countries regarding the roll-out of safe and effective vaccines, addressing transportation and deployment needs, and identifying priority groups.to ensure equitable and affordable access for all in the EU to an affordable vaccine as early as possible.to secure timely access to vaccines for Member States and their population while leading the global solidarity effort.to ensure the quality, safety and efficacy of vaccines.The objectives of the EU Vaccines Strategy are: With the vaccines strategy, the Commission supported efforts to make the process more efficient, resulting in this timeframe being reduced to less than one year for most vaccines. On 17 June 2020, the European Commission presented the EU Vaccines Strategy to accelerate the development, manufacturing and deployment of vaccines against COVID-19. This funding was considered a down-payment on the vaccines that Member States purchase. In return, the Commission financed a part of the upfront costs from the €2.7 billion Emergency Support Instrument. Through Advance Purchase Agreements with individual vaccine producers, the Commission secured the right to buy a specified number of vaccine doses in a given timeframe and at a given price. The Commission and Member States have taken a common EU approach to securing supplies and facilitating their distribution. Safe and effective vaccines against COVID-19 are the best way out of the pandemic.
0 kommentar(er)
